Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.6105 | 1 |
Mycobacterium ulcerans | bacterioferritin BfrA | 0.001 | 0 | 0.5 |
Treponema pallidum | bacterioferrin (TpF1) | 0.001 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.6105 | 1 |
Mycobacterium leprae | PROBABLE BACTERIOFERRITIN BFRA | 0.001 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.6105 | 1 |
Mycobacterium tuberculosis | Probable bacterioferritin BfrA | 0.001 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.6105 | 1 |
Onchocerca volvulus | Huntingtin homolog | 0.0119 | 1 | 0.5 |
Mycobacterium tuberculosis | Bacterioferritin BfrB | 0.001 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.6105 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 1 | 1 |
Onchocerca volvulus | Huntingtin homolog | 0.0119 | 1 | 0.5 |
Mycobacterium ulcerans | bacterioferritin BfrB | 0.001 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.6105 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.6105 | 1 |
Trichomonas vaginalis | ferritin, putative | 0.001 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | bacterioferritin/cytochrome b1 | 0.001 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | = 1 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.